Philips launches new IntraSight interventional applications platform to seamlessly integrate intravascular imaging and physio...
May 20 2019 - 3:59AM
May 20, 2019 Integrating best-in-class physiology,
imaging and co-registration tools across the interventional lab
workflow supports physicians in providing cardiac and peripheral
vascular patients with superior care
Amsterdam, The Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the launch of the new IntraSight interventional
applications platform. The secure, application-based platform
offers a comprehensive suite of clinically proven iFR, FFR, IVUS
and co-registration [1] modalities to simplify complex
interventions and speed routine procedures.
In image-guided treatments of the heart and peripheral blood
vessels, there is an increasing trend to use advanced catheters and
pressure wires that are capable of producing ultrasound images of
the interior of blood vessels (intravascular ultrasound or IVUS)
and perform blood pressure measurements (fractional flow reserve or
FFR and instant wave free ratio or iFR). There is a growing body of
clinical evidence that the use of such technologies in conjunction
with interventional X-ray improves patient outcomes.
“IntraSight has made an immediate impact in our lab,” said Dr.
Rasha Al-Lamee, Clinical Academic Interventional Cardiology
Consultant at Imperial College Healthcare NHS Trust, London, UK.
“It is so simple and intuitive to use that it took us no time at
all to get used to it. It has made using physiology and imaging
even quicker and easier, which is a great advance for us and for
our patients.”
Philips IntraSight optimizes lab performance with tableside
touchscreen control, systems integration, data management and
remote service diagnostics. The combination of IntraSight and
Azurion, Philips’ industry-leading image-guided therapy platform,
provides an unmatched level of diagnostic insight and intuitive
tableside control that enables clinicians to provide cardiac and
peripheral vascular patients with superior care. IntraSight
delivers an outstanding user experience with a modern, intuitive
interface that minimizes learning curves and increases workflow
confidence.
“The range and complexity of cardiovascular diseases that can be
treated with minimally invasive procedures continues to expand,”
said Bert van Meurs, Chief Business Leader Image Guided Therapy at
Royal Philips. “Correspondingly, the procedures themselves are also
becoming more complex, increasing the demands on physicians to
integrate different sources of information, decide on the best
course of treatment for each patient, act on that decision and
confirm the treatment’s effectiveness. IntraSight is an important
step forward in integrating intravascular diagnostic applications
into a smart, simple and seamless workflow in the interventional
lab.”
A significant advance in Philips’ unique portfolio of systems,
smart devices, software and services in image-guided therapy, the
scalable IntraSight platform is based on Philips’ common software
and hardware architecture.
Further providing seamless integration in the interventional
lab, Philips SyncVision, available on IntraSight [4], advances
patient care by mapping both the pressure profile and IVUS
measurements of the whole vessel onto the angiogram. With iFR
pullback and co-registration and IVUS co-registration [1],
physicians can identify the precise locations causing ischemia,
plan stent length and placement with a virtual stent, and predict
physiologic improvement.
iFR is an innovative pressure-derived index proprietary to
Philips, allowing a simplified hyperemia-free physiological
assessment of coronary blockages. It continues to be adopted into
clinical practice, with mounting evidence that this innovative
technology contributes to reducing costs, improving outcomes [2, 3,
4] and enhancing the patient experience. IntraSight, SyncVision and
iFR are part of Philips’ unique portfolio in image-guided therapy,
delivering sophisticated, procedure-oriented solutions to
healthcare providers.
IntraSight will be showcased at the SCAI scientific sessions,
booth #706 (19-22 May in Las Vegas, U.S.) and EuroPCR, booth #F15,
Level 1 (21-24 May in Paris, France. Visit the Philips booths at
these events to experience the company’s innovative cardiology
portfolio. Follow the #EuroPCR conversation at
@PhilipsLiveFrom.
[1] Co-registration tools available within IntraSight 7
configuration via SyncVision.[2] Davies JE, et al. Use of the
Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N
Engl J Med. 2017 May 11;376(19):1824-1834.[3] Gotberg M, et al. iFR
Swedeheart Investigators. Instantaneous Wave-free Ratio versus
Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May
11;376(19):1813-1823.[4] Patel M. “Cost-effectiveness of
Instantaneous Wave-free Ratio (iFR) compared with Fractional Flow
Reserve (FFR) to guide coronary revascularization decision making.”
Late-breaking Clinical Trial presentation at ACC on March 10,
2018.
For further information, please contact:
Mark GrovesPhilips Group Press OfficeTel: +31 631 639 916Email:
mark.groves@philips.comTwitter: mark_groves
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.comTwitter: FC_Feer
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2018
sales of EUR 18.1 billion and employs approximately 77,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips_IntraSight_Azurion_IVUS_Flexspot_monitor
- Philips_IntraSight_Azurion_TSM_monitor_lab
- Philips_IntraSight_Azurion
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From May 2023 to May 2024